Enzo Biochem — KOL Event December 17, 2020
33 slides from Enzo Biochem's conference presentation, Dec 17, 2020
Slide 1: COVID-19: The Vaccine is Out, Now What Does that Mean for Testing?
1 Scientists Enabling Healthcare Œ COVID - 19: The Vaccine is Out, Now What Does that Mean for Testing ? KOL Event December 17, 2020
Slide 2: Forward Looking Statements
2 Forward Looking Statements Except for historical information, the matters discussed in this presentation may be considered "forward - looking" statements within the meaning of Section 27 A of the Securities Act of 1933 , as amended, and Section 21 E of the Securities Exchange Act of 1934 , as amen
Slide 3: Elazar Rabbani, PhD
3 3 Elazar Rabbani, PhD Dr . Elazar Rabbani, PhD is an Enzo Biochem founder and has served as the Company's Chairman of the Board and Chief Executive Officer since its inception in 1976 . Dr . Rabbani has authored numerous scientific publications in the field of molecular biology, in particular, nuc
Slide 4: Introduction
Scientists Enabling Healthcare Œ Introduction
Slide 5: Company Snapshot
5 5 +40% YoY Revenue Growth FY21E ~ $115M 445 employees operating on a global basis 450+ Patents and Patent Applications Global HQ in NYC with a worldwide distribution network Diagnostic Product Development and manufacturing under GMP compliance, CAP Accredited & CLIA Certified Company Snapshot “ Ou
Slide 6: Capitalizing on industry tailwinds amid accelerated global demand for diagnostics
6 Capitalizing on industry tailwinds amid accelerated global demand for unique diagnostic platform technologies FY(JUL)’21 - reach profitability & $115m revenue run rate Expanded margin profile & product mix COVID - 19 Testing & Platform - Flexible Solutions Our rapid response provided tests in the
Slide 7: Extensive Capabilities Products & Services
7 Extensive Capabilities Products & Services DEEPSEE ® FISH Probes AMPIPROBE ® Assays Molecular Diagnostics CYTAG ® CGH Labeling Genetics & Genomics Immunoassays POLY - VIEW ® PLUS Detection Anatomical Pathology
Slide 8: Bruce Hanna, PhD
8 8 Bruce Hanna, PhD Bruce Hanna, PhD, has served as a Clinical Professor of Pathology and Clinical Professor of Microbiology at the New York University School of Medicine since 1979 and Adjunct Professor of Science at New York University College of Dentistry since 2010 . From 2006 to 2015 , he serv
Slide 9: A virus is a DNA/RNA delivery system into the host cell
9 A virus is a DNA/RNA delivery system into the host cell. The virus binds to a receptor on the host cell, enters the cell and replicates. (lysogenic cycle). Angiotensin - converting enzyme 2 (ACE2) a ttached to the membrane of host cells located in many parts of the body including the lungs, arteri
Slide 10: SARS-CoV-2 Targets For Diagnostic Tests And Vaccines
10 mRNA vaccine immunogen Antibody Test Target Serologic test ELISA Antigen test determinants Molecular test determinants SARS - CoV - 2 Targets For Diagnostic Tests And Vaccines
Slide 11: How To Test Patients For COVID Infection
11 How To Test Patients Fo r COVID - 19 Infection — acquire the pathogen & it persists aka latent/incubation period – vaccine effect unknown Disease – develop symptoms from mild to severe m - RNA vaccines 95% effective preventing The positive and negative percent agreements between the AMPIPROBE SAR
Slide 12: Not all tests are the same
12 “Not all tests are the same” Molecular Test Antibody Test Antigen Test (Gold Standard) (Post - virus ) (Faster Results) Ampiprobe ® Commercially Approved – US IgG/IgM ELISA Commercially Approved – US Sample Types Nasal, Throat & Saliva Blood Draw; finger stick Nasal, Throat & Saliva Advantages Ve
Slide 13: Interim Guidance for Antigen Testing for SARS-CoV-2
13 Interim Guidance for Antigen Testing for SARS - CoV - 2 Updated Dec. 5, 2020
Slide 14: Enzo's molecular solutions using RT-PCR
14 Enzo’s molecular solutions using RT - PCR AMPICOLLECT for sample collection AMPIXTRACT SARS - CoV - 2 Extraction Kit for sample processing - nucleic acid extraction from patient specimens AMPIPROBE SARS - CoV - 2 Assay Kit and Controls for amplification and detection AMPIPROBE SARS - CoV - 2 Test
Slide 15: Antibody Test (Blood) by ELISA
15 Antibody Test (Blood) by ELISA Detect immune response to past SARS - CoV - 2 exposure or disease (seroconversion) Enzo SARS - CoV - 2 ELISA Sensitivity = 100% Specificity = 96.5%
Slide 16: Issues Post Vaccine: How will testing algorithms be modified?
16 Issues Post Vaccine: How will testing algorithms be modified? • Vaccine acceptance : incidence of adverse reaction - time to herd immunity • Will the virus mutate : i.e. in humans or in the animal reservoir • Antibody testing will become standard of practice - do Ab positive patients, from prior
Slide 17: Gerard Nuovo, MD
17 17 Gerard Nuovo, MD Dr . Gerard Nuovo is a Professor of Pathology at the Wexner Medical Center at Ohio State University and a board - certified anatomic pathologist . He has spent his entire 30 + year career correlating the histologic features with the in situ detection of DNA, RNA, and proteins
Slide 18: Complete, Affordable Solutions for COVID
18 Complete, Affordable Solutions for COVID - 19 Enzo is well - equipped to provide the testing, processing and detection/analytics for this large and growing market Inflammation ELISA test that relies on a cytokine storm panel for monitoring Virus Detection Proprietary Molecular Diagnostic Kits off
Slide 19: Cytokine Storm Immunoassay for Inflammation Monitoring
19 Inflammation • Commercialization of full inflammation panel including detection of Interleukin 6 (IL - 6) levels to enable administration of immunosuppressant to treat Coronavirus patients demonstrating hyper immune response • Enzo 96 - well ELISA plate test is performed in a clinical lab using c
Slide 20: Pathophysiology of SARS-CoV2 infection
20 Pathophysiology of SARS - CoV2 infection Gerard Nuovo, MD and Cynthia Magro , MD (Professor of Pathology, Cornell Medical Center) • Initial infection in the nasopharynx by SARS - CoV2
Slide 21: Cytologic And Molecular Correlates Of SARS-CoV-2 Infection Of The Nasopharynx
21 Cytologic And Molecular Corelates Of SARS - CoV - 2 Infection Of The Nasopharynx x The target cell of the COVID - 19 virus is the ACE2+ GLANDULAR CELL of the nasal cavity x The infected cells contain very large amounts of infectious virus, which kills the cell x This allows for a strong immune re
Slide 22: Cytologic And Molecular Correlates Of SARS-CoV-2 Infection Of The Nasopharynx
22 Cytologic And Molecular Corelates Of SARS - CoV - 2 Infection Of The Nasopharynx Normal nasal smear COVID 19 nasal smear SPIKE protein MAIN FINDINGS
Slide 23: Pathophysiology of SARS-CoV2 infection
23 Pathophysiology of SARS - CoV2 infection Gerard Nuovo, MD and Cynthia Magro , MD (Professor of Pathology, Cornell Medical Center) • Infection in lung associated with massive infection and complement mediated death of virus Translational Research 2020; 220:113)
Slide 24: Virus Infection Of The Lung
24 Virus Infection Of The Lung x The target cells of the COVID - 19 virus in the lung are the ACE2+ macrophages, endothelia, and alveolar pneumocytes x The infected cells contain very large amounts of infectious virus x The body’s response is to activate complement cascade which causes small blood c
Slide 25: SARS-CoV-2 Infection Of The Lung
25 SARS - CoV - 2 Infection Of The Lung Infected macrophage Infection spreads to endothelial cells Degenerating virus MAIN FINDINGS
Slide 26: What is the consequence of the degenerated viral proteins entering the circulation?
26 WHAT IS THE CONSEQUENCE OF THE DEGENERATED VIRAL PROTEINS ENTERING THE CIRCULATION?
Slide 27: Circulating Viral Proteins Can Cause A Lot Of Damage
27 Circulating Viral Proteins Can Cause A Lot Of Damage x Viral spike protein enters circulation and binds to ACE2+ endothelia in microvessels x The sites with the highest amount of ACE2+ endothelia are the SKIN/FAT and brain (also heart, liver, kidney) x The docked spike protein kills the endotheli
Slide 28: Docked Spike Protein In The Skin
28 Docked Spike Protein In The Skin Viral capsid Viral RNA Viral RNA lung MAIN FINDINGS
Slide 29: What is the consequence of the degenerated viral proteins entering the circulation?
29 WHAT IS THE CONSEQUENCE OF THE DEGENERATED VIRAL PROTEINS ENTERING THE CIRCULATION?
Slide 30: Circulating Viral Proteins Can Cause A Lot Of Damage
30 Circulating Viral Proteins Can Cause A Lot Of Damage x This paper demonstrated that the observation of ACE2+ endothelia in microvessels was not limited to the subcutaneous fat of the skin x It was also found in the brain, liver, heart, and other organs x Again, the docked spike protein kills the
Slide 31: Conclusions
31 Conclusions x Large reservoirs of infectious virus are limited to the nasopharynx and lung x The microthrombi in lung kills virus, but this releases the spike (capsid) protein into the circulation (NOT infectious but still dangerous) x The docked spike protein kills the ACE2+ endothelial cell, ac
Slide 32: Questions & Answers
Scientists Enabling Healthcare Œ 32 Gerard Nuovo, MD Elazar Rabbani, PhD Bruce Hanna, PhD Questions & Answers
Slide 33: Thank You
Scientists Enabling Healthcare Œ Thank You www.enzo.com IR@enzo.com 33